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Abstract 
The role of gene-specific methylation in white blood cells (WBC) as a marker of breast cancer risk 
is currently unclear. We determined whether promoter hypermethylation in blood DNA of 
candidate tumor suppressor genes frequently methylated in breast tumors can be used as a 
surrogate biomarker for breast cancer risk. Promoter methylation of BRCA1, CDH1 and RARβ was 
analyzed in WBC DNA from a population-based sample of 1,021 breast cancer patients and 1,036 
controls by the MethyLight assay. Gene-specific promoter methylation in the DNA of 569 tumor 
tissue samples was also analyzed to determine the correlation of methylation levels with blood 
from the same individual. Hypermethylation of BRCA1 (OR: 1.31; 95% CI: 0.98-1.75) in WBC was 
associated with an increased risk of breast cancer when positive methylation was defined as ≥0.1% 
methylated. There was lack of concordance between tumor tissue and paired WBC DNA meth-
ylation. These results provide limited support that hypermethylation of BRCA1 in WBC DNA may 
be useful for determination of breast cancer risk. Additional studies with larger numbers of genes 
are needed to fully understand the relationship between WBC methylation and breast cancer risk. 
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Introduction 
Aberrant hypermethylation in promoter regions 
of genes is now recognized as an important and early 
event in carcinogenesis [1]. To date, CpG island hy-
permethylation has been shown to inactivate more 
than 70 genes in breast tumor tissues [2]. Among these 
genes, breast cancer-related tumor suppressor genes, 
BRCA1, CDH1 and RARβ are frequently hypermeth-
ylated in breast cancer [3-5]. Numerous studies have 
confirmed the hypothesis that aberrant methylation of 
specific genes contributes to the malignant phenotype 
of breast cancer [6-9]. 
It is increasingly recognized that tumor DNA can 
be found in the bloodstream of cancer patients and 
that this DNA frequently contains the same genetic 
and epigenetic alterations as DNA isolated from an 








tion of tumor DNA in blood may serve as an early and 
more accessible marker for diagnosis of breast cancer. 
However, the frequency of aberrant methylation in 
white blood cells (WBC) as a potential biomarker of 
risk has not been extensively investigated. We hy-
pothesized that aberrant promoter methylation of 
BRCA1, CDH1 and RARβ would be detectable in WBC 
DNA of breast cancer patients and there would be a 
correlation between methylation in tumor tissue and 
blood DNA but with more frequent methylation in 
tissue DNA.  
In the present study, we determined whether 
methylation in BRCA1, CDH1 and RARβ in WBC 
DNA differed between cases and controls in the Long 
Island Breast Cancer Study Project (LIBCSP). Since 
tumor methylation for these genes was available for a 
large subset of the cases, we also determined the cor-
relation between methylation status in tumor and 
WBC DNAs from cases.  
Materials and Methods  
Study population and data collection 
We utilized the resources from the case-control 
component of the LIBCSP, a population-based inves-
tigation. Details of the study participants and design 
have been described previously [13-15]. In brief, eli-
gible case participants included English speaking 
adult female residents of Nassau and Suffolk counties 
on Long Island, NY. Eligible case women were of all 
ages and races and newly diagnosed with in situ or 
invasive breast cancer between August 1, 1996, and 
July 31, 1997. Potentially eligible controls were fre-
quency-matched to the expected age distribution of 
the cases by 5-year age groups and identified through 
random digit dialing for women age <65 years and 
the Health Care Finance Administration rosters for 
women age ≥65 years. Controls were defined as 
women who resided in the same Long Island counties 
as the cases, but who had no personal history of breast 
cancer.  
The interviewer-administered structured case- 
control questionnaire was used to assess a number of 
personal, demographic and breast cancer-related 
characteristics. The questionnaire was completed by 
82.1% of eligible cases (n = 1,508) and 62.8% of eligible 
controls (n = 1,556) and was administered within a 
few months of diagnosis. Among women who com-
pleted the questionnaire, 73.1% of cases (n = 1,102) 
and 73.3% of controls (n = 1,141) donated a blood 
sample. Of these, 1,021 cases and 1,036 controls with 
enough DNA for MethyLight analysis were included 
in the present study. The study protocol was ap-
proved by the Institutional Review Boards of the col-
laborating institutions. 
Sample collection and DNA preparation  
Blood samples were collected at the time of the 
case-control interview by trained field staff and DNA 
was isolated from blood specimens using the methods 
previously described [15]. DNA was available for 
1,021 cases and 1,036 controls. Archived pathology 
blocks from 962 (63.8%) women were successfully 
retrieved from the 33 hospitals in the Long Island 
study area. Isolation of tumor tissues from paraffin 
sections and tumor DNA were as previously de-
scribed [16, 17]. 
 Methylation analysis 
DNAs first underwent bisulfite modification 
using the CpGnome DNA Modification Kit 
(Chemicon International, Purchase, NY) following the 
manufacturer’s protocol. Sodium bisulfite-treated 
WBC DNA was analyzed by the MethyLight tech-
nique as described previously [18]. The primers and 
probes for BRCA1, CDH1, RARβ and β-actin (ACTB) 
were previously described [10. 19, 20]. Specificity of 
the reactions for methylated DNA was confirmed 
separately using CpGenomeTM Universal methylated 
and unmethylated DNAs (Chemicon, MA, USA). 
Relative quantification was determined based on the 
threshold cycles of the gene of interest and of the in-
ternal reference gene. The percentage of methylation 
at a specific locus was calculated by the 2-ΔΔCT method 
[21]. For the 2-ΔΔCT method to be valid, the amplifica-
tion efficiencies of the test genes and reference gene, 
ACTB must be approximately equal. This was exam-
ined using real-time PCR and Taqman detection of 
serial dilutions of DNA with a 100-fold range and 
gene-specific primers of each gene and ACTB. The 
ΔCT (CT,Target gene - CT,Reference) was calculated for each 
DNA dilution and a plot of the log DNA dilution vs 
ΔCT was made. All amplification efficiencies were 
similar (data not shown). All samples were assayed in 
duplicate and the MethyLight assay was further val-
idated by using mixtures of fully methylated and 
unmethylated DNA to give 0, 0.1, 0.5, 1, 5, 10, 25, 50 or 
100% methylation.  
Methylation data obtained from tumor tissue 
DNAs have been described in prior publications 
[16,17]. Among women who donated blood, tumor 
tissue data were available for 569, 515 and 515 cases 
for BRCA1, CDH1 and RARβ, respectively. BRCA1 
methylation in tumor tissue was determined by 
methylation-specific PCR (MSP) as described previ-
ously [16]. The CpG sites of BRCA1 covered in MSP 
were overlapped with those measured with the Me-
thyLight assay. The MethyLight assay was used for 
determining the methylation status of CDH1 and 
RARβ in tumor tissue as described previously [17].  





Statistical analysis was performed using the SAS 
9.1 (Cary, NC). The χ2 test was used to examine dif-
ferences in the distributions of variables between 
cases and controls with methylation data. Among 
those with WBC methylation data, there were no sig-
nificant case-control differences in the distributions of 
menopausal status, but cases were more likely to re-
port a family history of breast cancer than controls 
(18.8% vs. 14.2%; P=0.006). Cases with tumor data on 
gene methylation did not differ in age or family his-
tory from those with WBC methylation data. Cases 
with BRCA1 methylation data were somewhat less 
frequently postmenopausal (62%) than those with 
data on CDH1 and RARβ (66%).  
Odds ratios (ORs) and corresponding 95% con-
fidence intervals (CIs) for the association between 
methylation status and breast cancer risk were esti-
mated by unconditional logistic regression [22]. We 
explored several constructions for the methylation 
exposure variable including binary models, where 
methylation status by MethyLight was categorized as 
positive if values were ≥1%, ≥0.5%, and ≥0.1%, re-
spectively; a 3-level categorical model (unmethylated, 
<1% methylated, and ≥1% methylated); as well as 
continuous modeling. Potential confounders of the 
methylation-breast cancer association were identified 
though the literature and included: first degree family 
history of breast cancer (yes/no); body mass index 
(BMI = weight in kilograms/height in meters 
squared) (categorical); physical activity (categorical); 
smoking history (ever/never); and alcohol history 
(ever/never). Covariates were included in the final 
model if their inclusion changed the exposure esti-
mate by >10% [23]. Only family history of breast can-
cer, BMI and physical activity altered the estimate by 
greater than 10%. Final models were therefore ad-
justed for each of these variables as well as 5-year age 
group.  
The kappa coefficient (and corresponding 95% 
confidence intervals) was used to compare the pro-
portion of subjects defined as hypermethylated in 
WBC vs. tumor tissue for each of the three breast 
cancer-related tumor suppressor genes, BRCA1, 
CDH1 and RARβ [24]. 
Results  
BRCA1, CDH1 and RARβ were rarely methylated 
in WBC DNA from either cases or controls with only 
6, 2 and 1 subjects for BRCA1, CDH1 and RARβ, re-
spectively, when values of >10% were considered as 
positive. Using ≥1% as the cutoff for positive methyl-
ation, methylation frequencies of BRCA1, CDH1 and 
RARβ were 1.8%, 2.0% and 1.5%, in cases and 1.3%, 
1.1% and 1.5% in controls, respectively. In contrast, 
when we used the ≥0.1% cutoff to define positive 
methylation status we observed more frequent hy-
permethylation in WBC DNA for both cases and con-
trols (Table 1).  
We found little evidence of association between 
any of the genes and breast cancer risk modeling 
methylation as a continuous variable (Table 1). Given 
the low proportion of women classified as positive 
using ≥1% or ≥0.5% methylated definitions, our bi-
nary exposure models revealed non-significant asso-
ciations between hypermethylation of BRCA1, CDH1 
and RARβ and breast cancer risk. We did, however, 
find evidence of association upon classifying women 
with ≥0.1% methylation as positive. Hypermethyla-
tion of BRCA1 (OR: 1.31; 95% CI: 0.98-1.75) was asso-
ciated with increased risk of breast cancer, while hy-
permethylation of CDH1 (OR: 0.65; 95% CI: 0.54-0.79) 
and RARβ (OR: 0.67; 95% CI: 0.55-0.81) was associated 
with reduced risk (Table 1). Our three-level categori-
cal model revealed similar modest inverse associa-
tions with breast cancer risk for RARβ (Table 1).  
Table 1. Hypermethylation in white blood cell DNA in breast cancer cases and controls, Long Island Breast Cancer Study Project, 
1996-1997. 
 BRCA1 CDH1 RARβ 
 Case/Control ORa 95% CI Case/Control ORa 95% CI Case/Control ORa 95% CI 
Continuous Model 1021/1036 1.03 (0.98, 1.09) 1021/1036 1.04 (0.86, 1.26) 1021/1036 0.89 (0.68, 1.17) 
Binary Models          
Un-Methylated 1003/1023 1 Reference 1001/1025 1 Reference 1006/1020 1 Reference 
≥1% Methylated 18/13 1.22 (0.57, 2.60) 20/11 1.73 (0.76, 3.94) 15/16 0.62 (0.29, 1.34) 
          
Un-Methylated 985/1004 1 Reference 959/969 1 Reference 976/995 1 Reference 
≥0.5% Methylated 36/32 1.07 (0.64, 1.78) 62/67 0.73 (0.49, 1.07) 45/41 0.81 (0.51, 1.30) 
          
Un-Methylated 894/932 1 Reference 426/352 1 Reference 688/632 1 Reference 
≥0.1% Methylated 127/104 1.31 (0.98, 1.75) 595/684 0.65 (0.54, 0.79) 333/404 0.67 (0.55, 0.81) 
Categorical Model          
Un-Methylated 894/932 1 Reference 426/352 1 Reference 688/632 1 Reference 
0.1-<1% Methylation 109/91 1.32 (0.97, 1.80) 575/673 0.65 (0.53, 0.78) 318/388 0.64 (0.55, 0.82) 
≥ 1% Methylation 18/13 1.25 (0.58, 2.67) 20/11 1.29 (0.56, 2.97) 15/16 0.53 (0.24, 1.14) 
a Odds ratio: adjusted for age, family history, body mass index and physical activity 
 




Table 2. Promoter hypermethylation in breast tumors, among cases, and paired white blood cell DNA using >0.1% methylated as 
classification for +/- in blood. Long Island Breast Cancer Study Project, 1996-1997. 
 Number of cases (%) 
 BRCA1 CDH1 RARβ 
Methylation Statusa    
 Tumor, UMb / WBCc, UM 202 (35.5) 166 (32.2) 184 (35.7) 
 Tumor, UM / WBC, Md 29 (5.1) 230 (44.7) 102 (19.8) 
 Tumor, M / WBC, UM  288 (50.6) 41 (8.0) 148 (28.8) 
 Tumor, M / WBC M 50 (8.8) 78 (15.1) 81 (15.7) 
    
Kappa Statistic (95% CIe) 0.019 (-0.030, 0.068) 0.048 (-0.016, 0.112) -0.003 (-0.088, 0.082) 
a Promoter methylation in tumor tissue was classified as +/- for BRCA1 and ≥4% for CDH1 and RARβ 
b Unmethylated 
c White Blood Cell 
d Methylated 
e Confidence Interval 
 
We previously analyzed promoter hypermeth-
ylation in tumor tissues for BRCA1, CDH1 and RARβ 
[16, 17]. Tumor tissues were more frequently hyper-
methylated (defined as >4% methylation) than blood 
DNA for all genes tested (59.3% for BRCA1 [16], 23.3% 
for CDH1 [17] and 44.5% for RARβ [17]). Methylation 
of all three genes was discordant between tumor tis-
sue and paired WBC DNA using ≥0.1% methylated as 
the cutoff for positive methylation status in WBC 
(Table 2).  
Discussion 
In a large population-based, case-control study 
of women with breast cancer, we found that hyper-
methylation of BRCA1 may be associated with breast 
cancer risk when using very low levels of methylation 
(i.e. ≥0.1%) as the cutoff for comparison. Although 
two prior studies reported a significantly higher fre-
quency of WBC BRCA1 methylation in breast cancer 
cases [25, 26], two others found no difference [27, 28]. 
In contrast, WBC BRCA1 methylation at levels as high 
as 17% has been consistently observed in 5-43% of 
women with BRCA1 mutation-associated pathology 
but without germline BRCA1 mutations, suggesting 
rare constitutional methylation [25, 29]. Two studies 
have also suggested that methylation of specific re-
gions in ATM may be associated with increased breast 
cancer risk [30, 31]. An analysis of 25 genes reported 
that methylation of five genes (ZNF217, NEUROD1, 
SFRP1, TITF1 and NUP155) in WBC was associated 
with breast cancer risk [32]. The original 25 genes 
were selected because they are estrogen receptor-α 
targets, known to be differently methylated depend-
ing on hormone receptor status, known to contain 
stem cell polycomb group targets or known to be 
methylated in breast cancer. 
Here we used the MethyLight assay to deter-
mine WBC methylation for three candidate genes 
frequently methylated in breast cancer. This method 
allows rapid analysis of large numbers of samples and 
provides continuous data on % methylation calculat-
ed versus a “fully methylated” standard sample, 
which in this study was purchased from a commercial 
source. Previously, we have analyzed methylation for 
this type of material and found methylation levels 
ranging from 85-95%. This suggests that levels of 
methylation may not be accurate although relative 
methylation levels should be valid. In addition, there 
is no generally accepted cutoff for use in determining 
hypermethylation in WBC DNA. In our prior study of 
tumor tissue, we used 4% methylation as the cutoff 
since this value had been used previously [33]. 
However, one recent study used 0.1% methylation as 
the cutoff with cancer samples [34]. Thus, for WBC 
methylation we tested different cutoffs for the defini-
tion of hypermethylation including ≥1%, 0.5% or 
0.1%. While the number of subjects with hypermeth-
ylation increased as the cutoff was lowered, only for 
BRCA1 was there a suggestion of a positive associa-
tion between hypermethylation and breast cancer 
risk. The inverse relationships between methylation of 
CDH1 and RARβ and breast cancer risk are difficult to 
explain. Many more controls are considered positive 
for methylation when using the criteria ≥ 0.1% in 
CDH1 (n=684) and RARβ (n=404) than for BRCA1 
(n=104) and how this impacts results is unclear. The 
OR for CDH1 became inverted as the cutoff was low-
ered suggesting the data are unstable. In addition, the 
biological relevance of these very low levels of meth-
ylation is also unclear suggesting the results should be 
interpreted with caution.  
Our results showed a discordance of hyper-
methylation of the genes tested between WBC and 
tumor tissue, similar to results observed previously 
for BRCA1 [35]. This finding suggests that a direct link 
between WBC BRCA1 methylation and development 
of breast cancer is still questionable.  
One of the strengths of our study is the large 
sample size from a population-based case-control 
study (1,021 cases and 1,036 controls). In addition, the 
MethyLight assay we used is known to be sufficiently 
sensitive to detect methylated DNA present at low 




levels. However, despite these strengths, analyses 
were based on small numbers of women with hy-
permethylation because WBC DNA was rarely hy-
permethylated. Furthermore, the relatively modest 
number of tumor suppressor genes investigated pre-
cluded further analyses of the possible relationship 
between methylation levels and breast cancer risk. 
Thus, further studies with additional genes are 
needed to establish the usefulness of WBC DNA 
methylation as a marker of risk.  
In conclusion, we examined methylation levels 
in tumor and WBC DNA from in situ or invasive 
ductal breast cancer patients and in WBC DNA from 
population-based controls to identify epigenetic 
markers of breast cancer risk. Obtained results sug-
gest that hypermethylation of these three genes in 
WBC DNA may be associated with breast cancer risk, 
but additional studies on the biological significance of 
low-level methylation is needed to fully understand 
the observed results.  
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